Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

345700 Ganciclovir - CAS 82410-32-0 - Calbiochem

Ganciclovir, CAS 82410-32-0, is a nucleoside analog related to Acyclovir. Acts as a prodrug that is activated by phosphorylation. Inhibits the replication of cytomegalovirus (CMV; IC50 = 10 nM).

Ganciclovir - CAS 82410-32-0 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine

Primary Target: Acts as a prodrug that is activated by phosphorylation
345700
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
82410-32-0C₉H₁₃N₅O₄

Products

Número de referenciaEmbalaje Cant./Env.
345700-50MG Frasco de vidrio 50 mg
Description
OverviewA nucleoside analog structurally related to Acyclovir (Cat. No. 114798). Acts as a prodrug that is activated by phosphorylation. Has been used in the study of “suicide” gene therapy in cancer research. Upon expression of a viral suicide gene encoding herpes simplex virus, thymidine kinase (TK), the non-toxic prodrug ganciclovir, is converted to an active phosphorylated analog that can be incorporated into the DNA of replicating eukaryotic cells, causing death of the malignant dividing cell. Causes an irreversible cell cycle arrest at the G2/M checkpoint. Has also been used to study the loss of telomeres and to evaluate sensitivity of viruses to antiviral agents.
Catalogue Number345700
Brand Family Calbiochem®
Synonyms9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
References
ReferencesAghi, M., et al. 2000. J. Gene Med. 2, 148.
Qiao, J., et al. 2000. Hum. Gene Ther. 11, 1569.
Cannon, J.S., et al. 1999. J. Virol. 73, 4786.
Rubsam, L.Z., et al. 1999. Cancer Res. 59, 669.
Sprung, C.N., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 6781.
Yamasaki, H., et al. 1999. C.R. Acad. Sci. III 322, 151.
Halloran, P.J., and Fenton, R.G. 1998. Cancer Res. 58, 3855.
Product Information
CAS number82410-32-0
ATP CompetitiveN
FormWhite solid
Hill FormulaC₉H₁₃N₅O₄
Chemical formulaC₉H₁₃N₅O₄
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationGanciclovir, CAS 82410-32-0, is a nucleoside analog related to Acyclovir. Acts as a prodrug that is activated by phosphorylation. Inhibits the replication of cytomegalovirus (CMV; IC50 = 10 nM).
Biological Information
Primary TargetActs as a prodrug that is activated by phosphorylation
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSMF8407000
Safety Information
R PhraseR: 46-60-61

May cause heritable genetic damage.
May impair fertility.
May cause harm to the unborn child.
S PhraseS: 36/37/39-45-53

Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Avoid exposure - obtain special instructions before use.
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Carcinogenic / Teratogenic
Storage -20°C
Protect from Moisture Protect from moisture
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
345700-50MG 04055977194500

Documentation

Ganciclovir - CAS 82410-32-0 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Ganciclovir - CAS 82410-32-0 - Calbiochem Certificados de análisis

CargoNúmero de lote
345700

Referencias bibliográficas

Visión general referencias
Aghi, M., et al. 2000. J. Gene Med. 2, 148.
Qiao, J., et al. 2000. Hum. Gene Ther. 11, 1569.
Cannon, J.S., et al. 1999. J. Virol. 73, 4786.
Rubsam, L.Z., et al. 1999. Cancer Res. 59, 669.
Sprung, C.N., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 6781.
Yamasaki, H., et al. 1999. C.R. Acad. Sci. III 322, 151.
Halloran, P.J., and Fenton, R.G. 1998. Cancer Res. 58, 3855.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision16-November-2007 JSW
Synonyms9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
DescriptionA nucleoside analog that is structurally related to Acyclovir (Cat. No. 114798). Acts as a pro-drug that is activated by phosphorylation. It has been used in the study of "suicide gene therapy" in cancer research. Upon expression of a viral suicide gene encoding herpes simplex virus thymidine kinase (TK), the non-toxic pro-drug is converted to the phosphorylated active analog and is incorporated into the DNA of replicating eukaryotic cells, causing death of the dividing malignant cells. Causes an irreversible cell cycle arrest at the G2/M checkpoint. Has also been used to study the loss of telomers and to evaluate the sensitivity of viruses to anti-viral agents.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number82410-32-0
RTECSMF8407000
Chemical formulaC₉H₁₃N₅O₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (5 mg/ml) or H₂O (2 mg/ml)
Storage Protect from moisture
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Carcinogenic / Teratogenic
Merck USA index14, 4363
ReferencesAghi, M., et al. 2000. J. Gene Med. 2, 148.
Qiao, J., et al. 2000. Hum. Gene Ther. 11, 1569.
Cannon, J.S., et al. 1999. J. Virol. 73, 4786.
Rubsam, L.Z., et al. 1999. Cancer Res. 59, 669.
Sprung, C.N., et al. 1999. Proc. Natl. Acad. Sci. USA 96, 6781.
Yamasaki, H., et al. 1999. C.R. Acad. Sci. III 322, 151.
Halloran, P.J., and Fenton, R.G. 1998. Cancer Res. 58, 3855.